Baseline characteristics and treatment during the first 3year period of disease course stratified by calendar time.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Baseline characteristics | 1985-1994n: 207 | 1995-2004n: 472 | 2005-2014n: 237 |  p |
| Age, yrs, median (IQR) | 34 (18) | 39 (19) | 36 (21) | 0.003 |
| Disease duration, yrs, median (IQR) | 2 (9) | 2 (6) | 2 (7) | 0.10 |
| SLEDAI, median (IQR) | 4 (6) | 2 (6) | 2 (4) | < 0.001 |
| M-SLEDAI, median (IQR) | 2 (4) | 0 (4) | 0 (4) | < 0.001 |
| PGA, median (IQR) | 1 (1.3) | 1 (1.5) | 0.5 (1.5) |  0.59 |
| Female sex, n (%) | 190 (91.8) | 431 (91.3) | 214 (90.3) |  0.85 |
| Caucasian, n (%) | 96 (46.4) | 277 (58.7) | 125(52.7) |  0.01 |
| African American, n(%) | 110 (53.1) | 160 (33.9) | 86 (36.3) | < 0.001 |
| Higher education, n (%) | 93 (44.9) | 303 (64.2) | 169 (71.3) | < 0.001 |
| Smoking, n (%) | 49 (23.7) | 65 (13.8) | 24 (10.1) | < 0.001 |
| Treatment during 3/.year period |  |  |  |  |
| Immunosuppresive drug treatment, n (%)Ever received, ≥ 75% of visits,  | 79 (38.2) 31 (15) | 239 (50.6) 132 (28) | 137 (57.8) 93 (39.2) | < 0.001< 0.001 |
| Hydroxychloroquine, n (%)Ever received≥ 75% of visits | 124 (59.9) 58 (28) |  357 (75.6) 286 (60.6) | 222 (93.7)204 (86.1) | < 0.001< 0.001 |
| Prednisone, n (%)Ever received≥ 75% of visits | 185 (89.4) 147 (71) |  334 (70.8) 224 (47.5) | 158 (66.7) 96 (40.5) | < 0.001< 0.001 |

IQR: Interquartile range; SLEDAI: SLE Disease Activity Index; M-SLEDAI: Modified SLEDAI; PGA: Physician Global Assessment